Navigation Links
Vapotherm(R) Announces Validation of U.S. Patent
Date:1/22/2008

VAPOTHERM REINFORCES LEADERSHIP ROLE WITH PATENT FOR APPARATUS AND METHOD FOR RESPIRATORY TRACT THERAPY

STEVENSVILLE, Md., Jan. 22 /PRNewswire-USNewswire/ -- Vapotherm, the global leader in High Flow Oxygen Therapy products, announced today that U.S. patent rights have been validated for an apparatus used in the delivery tube technology for respiratory tract therapy. Reinforcing Vapotherm's principal role in the industry, the U.S. Patent No. 7,314,046 B2 has been granted through 2022 and provides Vapotherm the right to prevent or exclude other companies from making, using, selling, or offering to sell or import the invention.

The triple lumen design is the vital component for Vapotherm products as it helps deliver humidified air to the respiratory tract of patients. Used throughout all Vapotherm products, including the 2000i and the recently introduced Precision Flow(TM), the apparatus allows Vapotherm to maintain the conditioned breathing gases to the patient and thus aid with respiratory tract therapy and treatment.

"Our patient delivery circuit design is unique in the field and provides Vapotherm with a competitive advantage through the delivery of optimally conditioned breathing gases all the way to the patient, whereas conventional approaches can result in significant temperature and humidity loss," said William Niland, Chairman and Chief Business Development Officer at Vapotherm.

Vapotherm, Inc. is a privately held manufacturer of respiratory care devices for hospitals and home care use based in Stevensville, Maryland. The Company is dedicated to the development of innovative, noninvasive technologies for respiratory therapy, especially for the treatment of chronic lung and acute breathing disorders. For more information, visit http://www.vtherm.com.

CONTACT:

Amy Elias/Brian Johnson

Profiles, Inc.

410-243-3790

amy@profilespr.com

brian@profilespr.com


'/>"/>
SOURCE Vapotherm, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... Parallel ... clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module ... circle with the physician and clinical trial team. , Using the CONSULT module, patients ...
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
Breaking Biology Technology:
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
Breaking Biology News(10 mins):